⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IONS News
Ionis Pharmaceuticals, Inc. Common Stock
Biogen Completes Acquisition of Alcyone Therapeutics
globenewswire.com
BIIB
IONS
DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)
businesswire.com
IONS
Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes
businesswire.com
IONS
Ionis to present at upcoming investor conferences
businesswire.com
IONS
Ionis Announces Proposed Convertible Offering to Refinance 2026 Convertible Notes
businesswire.com
IONS
Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions
businesswire.com
IONS
Ionis presents new data demonstrating long-term disease control with DAWNZERA™ (donidalorsen) at ACAAI 2025 Annual Meeting
businesswire.com
IONS
Ionis reports third quarter 2025 financial results and highlights progress on key programs
businesswire.com
IONS
Detailed data from the landmark CORE and CORE2 pivotal studies of olezarsen for sHTG to be presented as a late breaker at AHA Scientific Sessions
businesswire.com
IONS
Ionis to hold third quarter 2025 financial results webcast
businesswire.com
IONS